Antibody Neutralization of Therapeutic Viruses

多发性骨髓瘤是一种无法治愈的，终末分化浆细胞的播散性恶性肿瘤， 在2006年造成超过11,000名美国人死亡。减毒麻疹病毒选择性地 对表达丰富的CD 46（病毒受体）的人骨髓瘤浆细胞具有破坏性， 在鼠骨髓瘤异种移植模型中具有治疗效力。因此，我们正在测试重组麻疹 在晚期难治性多发性骨髓瘤患者中静脉注射病毒。 中和性抗麻疹抗体预期会限制全身性抗麻疹抗体的治疗效果。 接种麻疹病毒，特别是在70%的抗体滴度较高的骨髓瘤患者中。的 该提案的目标是制定最佳策略，以对抗血液中的麻疹病毒中和 通过抑制抗麻疹抗体的产生，或者通过将病毒输送到自体免疫系统中， 单核细胞或树突细胞，在体外感染。这些研究的结果将用于指导 麻疹病毒治疗骨髓瘤患者的未来临床试验设计。具体目标如下： 目标1.开发一种临床可行的策略，使用环磷酰胺联合麻疹加强剂 接种疫苗以降低中和抗麻疹抗体的血浆浓度。 目标二。评价麻疹感染的单核细胞或单核细胞衍生的树突状细胞的性能 （未成熟或成熟）作为抗体抗性病毒递送载体。 目标3。确定CCR 7趋化因子受体表达的抑制是否可以有利地影响 麻疹感染的树突状细胞在CD 46转基因SCID小鼠中的生物分布。抗体是病毒作为抗癌剂成功应用的最重要障碍。这 格兰特寻求开发临床可行的解决方案来解决这个问题。

Multiple myeloma is an incurable, disseminated malignancy of terminally differentiated plasma cells that will be responsible for the deaths of more than 11,000 Americans in 2006. Attenuated measles viruses are selectively destructive to human myeloma plasma cells which express abundant CD46 (the viral receptor) and are therapeutically potent in murine myeloma xenograft models. We are therefore testing a recombinant measles virus by intravenous administration in patients with advanced, treatment-refractory multiple myeloma. Neutralizing antimeasles antibodies are expected to limit the therapeutic efficacy of the systemically administered measles viruses, particularly in those 70% of myeloma patients with higher antibody titers. The goal of this proposal is to develop optimal strategies to combat measles virus neutralization in the bloodstream by suppressing the production of antimeasles antibodies, or by delivering the virus inside autologous monocytes or dendritic cells, infected outside the body. The findings of these studies will be used to guide the design of future clinical trials of measles virotherapy in myeloma patients. Specific aims are as follows: Aim 1. Develop a clinically viable strategy using cyclophosphamide in combination with measles booster vaccination to reduce the plasma concentration of neutralizing anti-measles antibodies. Aim 2. Evaluate the performance of measles-infected monocytes, or monocyte-derived dendritic cells (immature or mature) as antibody-resistant virus delivery vehicles. Aim 3. Determine whether suppression of CCR7 chemokine receptor expression can favorably impact the biodistribution of measles-infected dendritic cells in CD46 transgenic SCID mice. Antibodies are the most important barrier to the successful deployment of viruses as anticancer agents. This grant seeks to develop clinical viable solutions to this problem.